Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 33

Cited In for PubMed (Select 8349820)

1.

Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.

Kumar R, Pan R, Upadhyay C, Mayr L, Cohen S, Wang XH, Balasubramanian P, Nádas A, Seaman MS, Zolla-Pazner S, Gorny MK, Kong XP, Hioe CE.

J Virol. 2015 Sep 1;89(17):9090-102. doi: 10.1128/JVI.01280-15. Epub 2015 Jun 24.

PMID:
26109728
2.

CD4 binding determinant mimicry for HIV vaccine design.

Nishiyama Y, Planque S, Hanson CV, Massey RJ, Paul S.

Front Immunol. 2012 Dec 17;3:383. doi: 10.3389/fimmu.2012.00383. eCollection 2012.

3.

Synergism between a CD4-mimic peptide and antibodies elicited by a constrained V3 peptide.

Moseri A, Tantry S, Ding FX, Naider F, Anglister J.

AIDS Res Hum Retroviruses. 2013 Apr;29(4):718-24. doi: 10.1089/AID.2012.0189. Epub 2012 Dec 26.

4.

Poxvirus vectors as HIV/AIDS vaccines in humans.

Gómez CE, Perdiguero B, Garcia-Arriaza J, Esteban M.

Hum Vaccin Immunother. 2012 Sep;8(9):1192-207. doi: 10.4161/hv.20778. Epub 2012 Aug 21. Review.

5.

Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.

Ketas TJ, Holuigue S, Matthews K, Moore JP, Klasse PJ.

Virology. 2012 Jan 5;422(1):22-36. doi: 10.1016/j.virol.2011.09.019. Epub 2011 Oct 22.

6.

Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.

Wu X, Sambor A, Nason MC, Yang ZY, Wu L, Zolla-Pazner S, Nabel GJ, Mascola JR.

Virology. 2008 Oct 25;380(2):285-95. doi: 10.1016/j.virol.2008.07.007. Epub 2008 Sep 18.

7.

Antibody-based HIV-1 vaccines: recent developments and future directions.

Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J; Working Group convened by the Global HIV Vaccine Enterprise.

PLoS Med. 2007 Dec;4(12):e348. No abstract available.

8.

Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Haynes BF, Montefiori DC.

Expert Rev Vaccines. 2006 Jun;5(3):347-63. Review.

9.

Comparing antigenicity and immunogenicity of engineered gp120.

Selvarajah S, Puffer B, Pantophlet R, Law M, Doms RW, Burton DR.

J Virol. 2005 Oct;79(19):12148-63.

10.

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR.

J Virol. 2004 Dec;78(23):13232-52.

12.
13.
14.
15.

Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.

Srivastava IK, Stamatatos L, Legg H, Kan E, Fong A, Coates SR, Leung L, Wininger M, Donnelly JJ, Ulmer JB, Barnett SW.

J Virol. 2002 Mar;76(6):2835-47.

17.
18.

Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.

Montefiori DC, Safrit JT, Lydy SL, Barry AP, Bilska M, Vo HT, Klein M, Tartaglia J, Robinson HL, Rovinski B.

J Virol. 2001 Jul;75(13):5879-90.

19.

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

Earl PL, Sugiura W, Montefiori DC, Broder CC, Lee SA, Wild C, Lifson J, Moss B.

J Virol. 2001 Jan;75(2):645-53.

20.

Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.

Richmond JF, Lu S, Santoro JC, Weng J, Hu SL, Montefiori DC, Robinson HL.

J Virol. 1998 Nov;72(11):9092-100.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk